375 related articles for article (PubMed ID: 26099628)
1. Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration.
Van Rompuy AS; Oliveras-Salvá M; Van der Perren A; Corti O; Van den Haute C; Baekelandt V
Mol Neurodegener; 2015 Jun; 10():23. PubMed ID: 26099628
[TBL] [Abstract][Full Text] [Related]
2. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
3. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
4. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.
Yamada M; Mizuno Y; Mochizuki H
Hum Gene Ther; 2005 Feb; 16(2):262-70. PubMed ID: 15761265
[TBL] [Abstract][Full Text] [Related]
5. Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase K-resistant alpha-synuclein.
Lu XH; Fleming SM; Meurers B; Ackerson LC; Mortazavi F; Lo V; Hernandez D; Sulzer D; Jackson GR; Maidment NT; Chesselet MF; Yang XW
J Neurosci; 2009 Feb; 29(7):1962-76. PubMed ID: 19228951
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
[TBL] [Abstract][Full Text] [Related]
8. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
Lo Bianco C; Schneider BL; Bauer M; Sajadi A; Brice A; Iwatsubo T; Aebischer P
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17510-5. PubMed ID: 15576511
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice.
Oliveras-Salvá M; Macchi F; Coessens V; Deleersnijder A; Gérard M; Van der Perren A; Van den Haute C; Baekelandt V
Neurobiol Aging; 2014 Nov; 35(11):2625-2636. PubMed ID: 25037286
[TBL] [Abstract][Full Text] [Related]
10. Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function.
Buck K; Landeck N; Ulusoy A; Majbour NK; El-Agnaf OM; Kirik D
Neurobiol Dis; 2015 Jun; 78():100-14. PubMed ID: 25818009
[TBL] [Abstract][Full Text] [Related]
11. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration.
Soria FN; Engeln M; Martinez-Vicente M; Glangetas C; López-González MJ; Dovero S; Dehay B; Normand E; Vila M; Favereaux A; Georges F; Lo Bianco C; Bezard E; Fernagut PO
Hum Mol Genet; 2017 Jul; 26(14):2603-2615. PubMed ID: 28520872
[TBL] [Abstract][Full Text] [Related]
12. Neuronal specificity of alpha-synuclein toxicity and effect of Parkin co-expression in primates.
Yasuda T; Miyachi S; Kitagawa R; Wada K; Nihira T; Ren YR; Hirai Y; Ageyama N; Terao K; Shimada T; Takada M; Mizuno Y; Mochizuki H
Neuroscience; 2007 Jan; 144(2):743-53. PubMed ID: 17101231
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Bian M; Liu J; Hong X; Yu M; Huang Y; Sheng Z; Fei J; Huang F
PLoS One; 2012; 7(6):e39953. PubMed ID: 22792139
[TBL] [Abstract][Full Text] [Related]
14. FOXO3 determines the accumulation of α-synuclein and controls the fate of dopaminergic neurons in the substantia nigra.
Pino E; Amamoto R; Zheng L; Cacquevel M; Sarria JC; Knott GW; Schneider BL
Hum Mol Genet; 2014 Mar; 23(6):1435-52. PubMed ID: 24158851
[TBL] [Abstract][Full Text] [Related]
15. Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra.
Garcia-Reitboeck P; Anichtchik O; Dalley JW; Ninkina N; Tofaris GK; Buchman VL; Spillantini MG
Exp Neurol; 2013 Oct; 248():541-5. PubMed ID: 23933574
[TBL] [Abstract][Full Text] [Related]
16. Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.
Yasuda T; Nihira T; Ren YR; Cao XQ; Wada K; Setsuie R; Kabuta T; Wada K; Hattori N; Mizuno Y; Mochizuki H
J Neurochem; 2009 Feb; 108(4):932-44. PubMed ID: 19141079
[TBL] [Abstract][Full Text] [Related]
17. Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration.
Zharikov A; Bai Q; De Miranda BR; Van Laar A; Greenamyre JT; Burton EA
Neurobiol Dis; 2019 May; 125():146-153. PubMed ID: 30658149
[TBL] [Abstract][Full Text] [Related]
18. Long-term overexpression of human wild-type and T240R mutant Parkin in rat substantia nigra induces progressive dopaminergic neurodegeneration.
Van Rompuy AS; Lobbestael E; Van der Perren A; Van den Haute C; Baekelandt V
J Neuropathol Exp Neurol; 2014 Feb; 73(2):159-74. PubMed ID: 24423640
[TBL] [Abstract][Full Text] [Related]
19. Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of Parkinson disease.
Yasuda T; Hayakawa H; Nihira T; Ren YR; Nakata Y; Nagai M; Hattori N; Miyake K; Takada M; Shimada T; Mizuno Y; Mochizuki H
J Neuropathol Exp Neurol; 2011 Aug; 70(8):686-97. PubMed ID: 21760537
[TBL] [Abstract][Full Text] [Related]
20. Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.
Song LK; Ma KL; Yuan YH; Mu Z; Song XY; Niu F; Han N; Chen NH
PLoS One; 2015; 10(6):e0131281. PubMed ID: 26114655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
